Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

OBJECTIVE: To evaluate the effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes mellitus inadequately controlled with metformin monotherapy. RESEARCH DESIGN AND METHODS: This was a double-blind, placebo-controlled, parallel-group, multicenter, dose-ranging study i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Rosenstock, Julio, Aggarwal, Naresh, Polidori, David, Zhao, Yue, Arbit, Deborah, Usiskin, Keith, Capuano, George, Canovatchel, William
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2012
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3357223/
https://ncbi.nlm.nih.gov/pubmed/22492586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc11-1926
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items